LYLars Andreas Rømo Ystaas

Lars Andreas Rømo Ystaas

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lars Andreas Rømo Ystaas has a total of 43 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Early-childhood temperament trajectories map onto transdiagnostic psychiatric risk

    by J. Kopal, N. R. Bakken, P. Parekh, A. A. Shadrin, P. Jaholkowski, L. A. R. Ystaas, N. Parker, O. B. Smeland, E. P. Tissink, I. E. Sønderby, et al.

    Early-childhood temperament is associated with later mental health. Temperament continues to develop throughout the first years of life, and a single assessment cannot capture its trajectory. Whether departures from an individual’s developmental trajectory carry psychiatric risk remains unknown. Using data from more than 50,000 children in the Norwegian Mother, Father and Child Cohort Study, we modeled longitudinal temperament at 1.5, 3, and 5 years of age with the FEMA-Long mixed-effects framework. We then quantified each child’s departures from their predicted trajectories. Multivariate analysis revealed two transdiagnostic dimensions linking trajectory departures to psychiatric diagnoses across childhood and adolescence. Higher scores on the first dimension were associated with an increased hazard of subsequent ADHD diagnosis (hazard ratio = 1.54), and higher scores on the second with an increased hazard of Asperger syndrome (hazard ratio = 1.64). To examine the genetic basis of these associations, we performed longitudinal GWAS of temperament and conjunctional FDR analysis to detect loci shared with the associated diagnoses. The effects of these loci changed across early childhood, with some strengthening and others attenuating with age. These findings show that departures from predicted temperament trajectories reflect transdiagnostic psychiatric risk with a shared genetic basis. Longitudinal, trajectory-based monitoring could help identify children at elevated psychiatric risk.

  • Open Access

    Genetic Liability to Addiction Underlies Comorbid Bipolar and Substance Use Disorders

    by Lars A.R. Ystaas, Pravesh Parekh, Nadine Parker, Ibrahim Akkouh, Viktoria Birkenæs, Ida E. Sønderby, Elise Koch, Espen Hagen, Oleksandr Frei, Alexey Shadrin, et al.

  • Open Access

    Early-childhood temperament deviations mark psychiatric risk into early adulthood

    by J. Kopal, N.R. Bakken, P. Parekh, A.A. Shadrin, P. Jaholkowski, L.A.R. Ystaas, N. Parker, O.B. Smeland, E.P. Tissink, I.E. Sønderby, et al.

    Early-childhood temperament is associated with mental health outcomes decades later. Temperament reflects early-emerging individual differences in emotional and behavioral tendencies. These differences are relatively stable across development and shaped by both genetic and environmental influences. However, the consequences of departures from expected developmental trajectories remain largely unexplored. Using data from more than 50,000 children in the Norwegian Mother, Father and Child Cohort Study, we modeled longitudinal temperament trajectories at 1.5, 3, and 5 years of age and quantified deviations from expected development. Multivariate pattern analysis revealed latent dimensions linking these deviations to clinical diagnoses, with ADHD as the most prominent outcome. Time-to-event analysis showed that these dimensions were associated with a higher hazard of ADHD diagnosis across childhood and adolescence. Finally, genetic analyses identified loci jointly associated with temperament trajectories and ADHD, revealing age-dependent genetic effects. Together, these findings show that deviations from temperament trajectories in early childhood capture transdiagnostic vulnerability across development. Early temperament monitoring may thus serve as an indicator of later mental health risk.

  • Open Access

    Genetic liability to addiction underlies comorbid bipolar and substance use disorders

    by Lars A. R. Ystaas, Pravesh Parekh, Nadine Parker, Ibrahim Akkouh, Viktoria Birkenæs, Ida E. Sønderby, Elise Koch, Espen Hagen, Oleksandr Frei, Alexey Shadrin, et al.

    Background: Bipolar disorder (BIP) frequently co-occurs with heightened substance use (SU) and substance use disorders (SUDs). Although the strong co-occurrence of these heritable traits points to shared genetic susceptibility, the extent to which there are differences in how SU and SUD overlap with BIP genetic architecture remains unclear. Methods: We quantified the polygenic overlap between BIP and SUDs (alcohol, cannabis, opioid, and tobacco), and BIP and SU traits (drinks per week, lifetime cannabis use, prescription_opioid use, and smoking initiation) using GWAS summary statistics and trivariate MiXeR. We then isolated the general and unique genetic contributions of SUD and SU using GWAS-by-subtraction via GenomicSEM. Next, we tested associations between polygenic risk scores (PRSs) derived from these latent factors and diagnostic and behavioral outcomes in the Norwegian Mother, Father and Child Cohort Study. Finally, we applied GSA-MiXeR to explore pleiotropic pathway enrichment shared between the latent factors and BIP. Results: We found extensive polygenic overlap between traits, with SUDs being more genetically correlated with BIP than SU traits. The unique SUD factor correlated positively with psychiatric disorders, whereas unique SU correlated negatively. PRSs for BIP, shared SUD/SU, and unique SUD were significantly associated with BIP, SUD, and comorbid SUD-BIP; PRS for unique SU was only associated with self-reported lifetime SU. GSA-MiXeR revealed richer gene-set enrichment for SUD/BIP than SU/BIP implicating dopamine signaling and interneuron function. Conclusion: By dissecting the genetic liability to SUD and SU and investigating their relationship with BIP we find a genetic link driven by substance dependence but not substance use more broadly.

  • Open Access

    Tropism Profiling of Lentiviral Vector Pseudotypes in Diverse Brain Tumor Models

    by Johannes K. Andersen, Lars A. R. Ystaas, Rolf Bjerkvig, Hrvoje Miletic, Jubayer A. Hossain

    Background: Lentiviral vectors (LVs) show promise as gene therapy tools for brain tumors, but optimal envelope protein choices for different tumor types have not been determined. Methodology: This study evaluated three pseudotyped LV variants—VSV-GP, FuG-B2, and LCMV-GP—across diverse brain tumor cell lines including glioblastoma (GBM), diffuse intrinsic pontine glioma (DIPG), medulloblastoma, and metastatic brain cancers. Results: VSV-GP and FuG-B2 pseudotypes significantly outperformed LCMV-GP across most tumor types. Both VSV-GP and FuG-B2 demonstrated high transduction efficiency in GBM and DIPG cells, though some cell lines displayed selective preferences for one pseudotype over the other. Medulloblastoma cells were challenging to transduce, with only VSV-GP achieving substantial efficacy. Metastatic brain cancers showed distinct tropism patterns: melanoma metastases were preferentially transduced by the FuG-B2 pseudotype, while lung metastases showed preference for the VSV-GP pseudotype. Conclusions: These findings suggest envelope protein selection should be tailored to specific brain tumor types. VSV-GP appears most suitable for medulloblastoma and lung metastases, FuG-B2 for melanoma metastases, and both for GBM and DIPG gene therapy applications. The study provides crucial guidance for translating lentiviral gene therapy to clinical applications, supporting personalized treatment strategies based on tumor-specific vector tropism profiles.

  • Open Access

    Gasdermin E in glioblastoma –pyroptosis resistance and tumor-promoting functions

    by Ege Solel, Egil Brudvik, Lars Andreas Rømo Ystaas, Yahaya A. Yabo, Emma Rigg, Romi Roy Choudhury, Halala Sdik Saed, Dieter Henrik Heiland, Rolf Bjerkvig, Jubayer Hossain, et al.

    Treatment of glioblastoma (GB), the most common and most aggressive malignant brain tumor, has made little progress over the past two decades. Despite extensive research on apoptosis and autophagy, necrotic cell death mechanisms like pyroptosis, which have the potential to stimulate anti-tumor immune responses, remain largely underexplored in GB. Here, we investigated whether Gasdermin E (GSDME)-mediated pyroptosis can be induced in GB by employing the drug raptinal, an inducer of cytochrome c release. Using human patient-derived and mouse GB cell lines, we showed that raptinal promotes GSMDE cleavage. However, although a strong pyroptotic response was observed in mouse cell lines, it was weak in human cell lines. This resistance was partially reversed by the calcium chelator BAPTA-AM, indicating that membrane repair mechanisms may counteract the pyroptotic response. Gsdme knockout (KO) in mouse GB cells unexpectedly prolonged the survival of immunocompetent mice, demonstrating a tumor-promoting role of GSDME independent of its pyroptotic function. Analysis of the immune microenvironment revealed that Gsdme KO promoted infiltration of T cells, which was confirmed by spatial transcriptomic analysis of GB patient samples. In addition, Gsdme/GSMDE KO reduced the invasive capacity of mouse/human GB cells. In conclusion, active membrane repair mechanisms may impair the pyroptotic efficacy in GB. GSDME has a tumor-promoting role in GB by suppressing T cell infiltration and increasing tumor cell invasion.